

Publications of the International Breast Cancer Study Group

Trial II

6. Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. *J Clin Oncol* 3:1059-1067, 1985. (Trial II)
8. Goldhirsch A, for the Ludwig Breast Cancer Study Group: Adjuvant treatment in operable breast cancer. *J Steroid Biochem* 23:1155-1160, 1985. (Trials I-IV)
9. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Hollaway L, Russel I and Rudenstam C-M: Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. *Hum Pathol* 16:1212-1218, 1985. (Trials I-IV)
11. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save-Soderbergh J, Holloway L, Russell I, Rudenstam C-M, for the Ludwig Breast Cancer Study Group: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. *Cancer* 58:2662-2670, 1986. (Trials I-IV)
13. Goldhirsch A and Gelber RD, for the Ludwig Breast Cancer Study Group: Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. *J Natl Cancer Inst Monogr* 1:55-70, 1986. (Trials I-IV)
14. Pedrazzini A, Gelber RD, Isley M, Castiglione M and Goldhirsch A, for the Ludwig Breast Cancer Study Group: First repeated bone scan in the observation of patients with operable breast cancer. *J Clin Oncol* 4:389-394, 1986. (Trials I-IV)
15. Hedley DW, Rugg CA, Gelber RD, for the Ludwig Breast Cancer Study Group: Association of DNA index and S-phase fraction with prognosis of N+ early breast cancer. *Cancer Res* 47:4729-4735, 1987. (Trials I-IV)
20. Goldhirsch A, Gelber RD, Castiglione M, for the Ludwig Breast Cancer Study Group: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. *J Clin Oncol* 6:89-97, 1988. (Trials I-II)
31. International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. *Ann Oncol* 1:30-35, 1990. (Trial II)
35. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. *Ann Oncol* 2:47-53, 1991. (Trials I-IV)
49. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam C-M, Collins J, Lindtner K, Gelber RD for the International Breast Cancer Study Group (formerly Ludwig Group): Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. *Ann Oncol* 3:733-740, 1992. (Trials I-V)
62. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, Reed R, Senn H-J, Goldhirsch A, Dyer MJS. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. *Ann Oncol* 5:409-414, 1994. (Trials I-IV)
63. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes, Forbes J, Simpson J, Tattersall MHN, Brunner K, Cavalli F, Senn HJ for the International Breast Cancer Study Group. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. *Ann Oncol* 5:717-724, 1994. (Trials I-IV)
67. Goldhirsch A, Gelber R, Price K, Castiglione M, Coates A, Rudenstam C-M, Collins J, Lindtner J, Hacking A, Marini G, Byrne M, Schnürch G, Brunner K, Tattersall MHN, Forbes J, Senn H-J for the International Breast Cancer Study Group: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. *Lancet* 343:377-381, 1994. (Trials I-V)
74. Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Cortés-Funes H, Gudgeon A, Simoncini E, Byrne M, Schnürch HG, Fey M, Tattersall MHN, Forbes JF, Cavalli F, Reed R, Senn H-J for the International (Ludwig) Breast Cancer Study Group (IBCSG): Routine tests during follow-up of patients after primary treatment for operable breast cancer. *Ann Oncol* 6:769-776, 1995. (Trials I-V)

75. Goldhirsch A, Gelber RD, Castiglione M, Price K, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Cavalli F, Galligioni E, Fey M, Gudgeon A, Cortés-Funes H, Tattersall M, Marini G, Byrne M, Snyder R, Forbes JF, Kay R, Hürny C, Thürlimann B, Reed R, Gusterson B, Torhorst J, Säve-Söderbergh J, Coates A for the International Breast Cancer Study Group. The best available adjuvant treatments are within the framework of clinical trials. *Isr J Med Sci* 31:145-154, 1995. (Trials I-V)
89. Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn H-J, Rudenstam C-M for the IBCSG. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. *Eur J Cancer* 33:2321-2325, 1997. (Trials I-V)
101. Colleoni M, Price K, Goldhirsch A, Castiglione-Gertsch M, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM, for the IBCSG. Dose-response effect of adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in node-positive breast cancer. *Eur J Cancer* 34:1693-1700, 1998. (Trials I-V)
105. Colleoni M, Price K, Castiglione-Gertsch M, Gelber R, Coates A, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, fluorouracil (CMF regimen). *Lancet* 354:130-131, 1999. (Trials I-VII)
108. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortés-Funes H, Veronesi A, Fey M, Rudenstam C-M, for the International (Ludwig) Breast Cancer Study Group. Identifying breast cancer patients at high risk for bone metastases. *J Clin Oncol*, 18: 3925-3935, 2000. (Trials I-VII)
112. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortés-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? *Lancet*, 355: 1869-1874, 2000. (Trials I-VI)
115. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A, for the International Breast Cancer Study Group. Early start of adjuvant chemotherapy improves treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptor. *J Clin Oncol* 18: 584-590, 2000. (Trials I-V)
119. Goldhirsch A, Gelber RD, Yothers G, Gray, RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. *J Natl Cancer Inst Monogr*, No. 30:44-51, 2001. (Trials I-VI)
126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)
134. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, and Collins J for the IBCSG. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I Through VII. *J Clin Oncol* 21:1205-1213, 2003. (Trials I-VII)
145. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Erzen D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, on behalf of the IBCSG. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15: 875-884, 2004. (Trials I-VII)
151. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the International Breast Cancer Study Group experience. *J Clin Oncol* 23:1390-1400, 2005. (Trials I-VII, IX) (Journal impact factor 9.8)
155. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687-1717, 2005. (Trials II, III, VI, VII, IX, 11-93) (Journal impact factor 21.7)
158. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A for the International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. *Lancet* 366:1108-1110, 2005. (Trials I, II, V, VI) (Journal impact factor 21.7)

169. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A for the IBCSG. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Ann Oncol* 17:935-944, 2006. (Trials I-IX) (Journal impact factor 4.3).
184. Karlsson P, Cole BF, Price, KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *J Clin Oncol* 25:2019-2026, 2007. (Trials I-IX) (Journal impact factor 11.8)
209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).